Search
SynOV1.1
go.drugbank.com/drugs/DB17539InvestigationalIt is a recombinant oncolytic adenovirus, controlled by synthetic gene circuit, encoding the human immunostimulating factor cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF).
SYNB1891
go.drugbank.com/drugs/DB17541InvestigationalSYNB1891 is a live, modified strain of the probiotic _Escherichia coli_ Nissle engineered to produce cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway.
IO-202
go.drugbank.com/drugs/DB17548InvestigationalIO-202 is a first-in-class antibody targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) member 4 (LILRB4).[A257276] It is being investigated in cancers.
Alrizomadlin
go.drugbank.com/drugs/DB17549InvestigationalAlrizomadlin is a novel MDM2 inhibitor that blocks the interaction of MDM2 and p53. It is being investigated in cancers.[A257281,A257286]
AGS-16C3F
go.drugbank.com/drugs/DB17551InvestigationalAGS-16C3F is under investigation in clinical trial NCT02639182 (A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma).
S65487
go.drugbank.com/drugs/DB17556InvestigationalS65487 a potent and selective BCL-2 inhibitor, and a prodrug of S55746.
Sovleplenib
go.drugbank.com/drugs/DB17557InvestigationalSovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting spleen tyrosine kinase (Syk).
Luveltamab tazevibulin
go.drugbank.com/drugs/DB17563Investigational[A257414] It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
Evorpacept
go.drugbank.com/drugs/DB17573InvestigationalEvorpacept is under investigation in clinical trial NCT04755244 (A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)).
Synonyms: A CD47-binding, fusion protein containing a high affinity engineered D1 domain of human signal regulatory protein alpha (SIRPalpha) variant 1 (v1) genetically linked to a modified and inactive Fc domainSS1(dsFv)-PE38
go.drugbank.com/drugs/DB17579InvestigationalSS1(dsFv)-PE38 is a recombinant anti-mesothelin immunotoxin. … SS1(dsFv)-PE38 is under investigation in clinical trial NCT01051934 (A Phase I Trial of SS1 (Dsfv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-small Cell Lung Adenocarcinoma